Vir Biotechnology (VIR) Equity Income (2021 - 2026)

Vir Biotechnology has disclosed Equity Income across 6 years of filings, most recently posting -$170000.0 for Q1 2026.

• Equity Income for Q1 2026 came in at -$170000.0, down 102.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.8 million (down 171.47% YoY), and the FY2025 annual result was $1.7 million, up 130.75% from the prior year.
• Equity Income came in at -$170000.0 for Q1 2026 at Vir Biotechnology, up from -$2.6 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $8.9 million in Q4 2022 to a low of -$95.0 million in Q1 2022.
• The 5-year median for Equity Income is -$2.6 million (2025), against an average of -$8.1 million.
• Peak annual rise in Equity Income reached 207.9% in 2025, while the deepest fall reached 945.5% in 2025.
• Vir Biotechnology's Equity Income stood at $8.9 million in 2022, then sank by 111.26% to -$1.0 million in 2023, then fell by 16.73% to -$1.2 million in 2024, then tumbled by 121.84% to -$2.6 million in 2025, then soared by 93.46% to -$170000.0 in 2026.
• The last three Equity Income figures came in at -$170000.0 (Q1 2026), -$2.6 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.